We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Gestational Lipid Profiles Associated with Adverse Cardiovascular Risk

By LabMedica International staff writers
Posted on 12 Jan 2021
Pregnancy has been proposed as a natural ‘stress test’ to predict the risk of cardiovascular disease (CVD) later in life. More...
The long-term effect of high blood pressure during pregnancy has been well established. Women who develop a hypertensive disorder of pregnancy such as gestational hypertension or pre-eclampsia have a 2–8 times higher risk of developing chronic hypertension and other diseases.

In pregnancy, lipid levels rise, leading to 30% higher levels of cholesterol, triglycerides and low density lipoprotein cholesterol at the end of the third term. The gestational lipid profile therefore shows resemblance to an atherogenic lipid profile. After delivery, lipid levels in general normalize to pre-pregnancy levels within three to four months.

Obstetricians and Gynecologists at the Erasmus University Medical Centre (Rotterdam, The Netherlands) and their colleagues performed an ongoing population-based prospective cohort study from early pregnancy and obtained plasma from 3,510 women from the Generation R study. The scientists measured lipid levels (total cholesterol, triglycerides and high-density lipoprotein cholesterol [HDL-c]), and low-density lipoprotein cholesterol (LDL-c), remnant cholesterol and non-HDL-c that were calculated in early pregnancy (median 13.2 weeks, 90% range [10.5 to 17.1]) and six years after pregnancy (median 6.5 years, 90% range [6.2 to 7.8]). Glucose levels, total cholesterol, triglycerides and HDL-c concentrations were measured with the Selectra E Chemistry Analyzer (Vital Scientific, Dieren, The Netherlands). Metabolic syndrome (MS) was assessed six years after pregnancy according to the NCEP/ATP3 criteria. They also examined the influence of pregnancy complications on these associations.

The scientists reported that gestational lipid levels were positively associated with corresponding lipid levels six years after pregnancy, independent of pregnancy complications. Six years after pregnancy the prevalence of MS was 10.0%; the prevalence was higher for women with a previous placental syndrome (13.5%). The most common feature of metabolic syndrome was low HDL-c (40.0%) followed by abdominal obesity (25.6%), high triglycerides (19.7%), a high blood pressure (19.0%), and high glucose levels (2.3%). Gestational triglycerides and remnant cholesterol in the highest quartile and HDL-c in the lowest quartile were associated with the highest risk for future MS, independent of smoking and body mass index.

The authors concluded that gestational lipid levels provide an insight in the future cardiovascular risk profile of women in later life. Monitoring and lifestyle intervention could be indicated in women with an unfavorable gestational lipid profile to optimize timely cardiovascular risk prevention. The study was published on December 23, 2020 in the journal BMC Medicine.

Related Links:
Erasmus University Medical Centre
Vital Scientific



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The MyChoice CDx test, currently used as a companion diagnostic in ovarian cancer, will generate the PrGIS score and is being advanced for use in prostate cancer. (Photo courtesy of Myriad Genetics)

Collaboration Advances Genomic Instability Biomarker for Prostate Cancer

In prostate cancer, homologous recombination deficiency is emerging as an important prognostic and predictive biomarker. Measuring the chromosomal instability associated with this pathway may help guide... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.